Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 18 of 18 publications.
Skip to main content
Danysh HE, Gilsenan A, Arana A, Pladevall-Vila M, Layton JB, Ziemiecki R, Chen H, Hunt PR, Johannes C. Validation of acute outcomes among patients with type 2 diabetes mellitus in the clinical practice research datalink. Poster presented at the Virtual ICPE 2021 Conference; August 23, 2021.
Layton JB, Ziemiecki R, Danysh HE, Gaber C, Gilsenan A, Johannes CB. Graphical representation of an array of quantitative bias analysis scenarios for differential outcome misclassification. Presented at the Virtual ICPE 2021 Conference; August 23, 2021.
Layton JB, Ziemiecki R, Danysh H, Gilsenan A, Johannes C. Graphical representation of multiple quantitative bias analysis scenarios for unmeasured confounding. Poster presented at the Virtual ICPE 2021 Conference; August 23, 2021.
Johannes C, Layton JB, Beachler DM, Ziemiecki RM, Li L, Danysh HE, Dinh J, Hunt PR, Karlsson C, Chen H, Gilsenan A. Risk of acute kidney injury in real-world use of dapagliflozin. Presented at the 2021 Virtual American Diabetes Association 81st Scientific Session; June 25, 2021.
Johannes C, Layton JB, Beachler DC, Ziemiecki RM, Li L, Danysh HE, Dinh J, Hunt PR, Karlsson C, Chen H, Gilsenan A. Risk of severe complications of urinary tract infection in real-world use of dapagliflozin. Poster presented at the 2021 Virtual American Diabetes Association 81st Scientific Session; June 25, 2021.
Forns J, Dudukina E, Hagg D, Szentkuti EP, Gembert K, Plana E, Gilsenan A, Horvath-Puho E, Reutfors J, Rebordosa C. Cohort study of the incidence of major cardiovascular events in new adult users of lisdexamfetamine and remote adult users of other attention-deficit/hyperactivity disorder treatments. Poster presented at the 2021 8th World Congress on ADHD Virtual Event; May 6, 2021.
Ruigomez A, Plana E, Gilsenan A, Fortuny J, Cainzos-Achirica M, Flynn RWV, MacDonald TM, Garcia-Rodriguez L, Ziemiecki R, Andrews EB. Identification and validation of major cardiovascular events in the United Kingdom data sources included in a multi-database post-authorization safety study of prucalopride. Drug Saf. 2021 May;44(5):541-51. doi: 10.1007/s40264-021-01044-4
Oppenheimer J, Slade DJ, Hahn BA, Zografos L, Gilsenan A, Richardson D, McSorley D, Lima R, Molfino NA, Averell CM. Real-world evidence: patient views on asthma in respiratory specialist clinics in America. Ann Allergy Asthma Immunol. 2021 Apr;126(4):385-93. doi: 10.1016/j.anai.2020.12.015
Arana A, Margulis AV, Varas-Lorenzo C, Bui CL, Gilsenan A, McQuay LJ, Reynolds M, Rebordosa C, Franks B, de Vogel S, Appenteng K, Perez-Gutthann S. Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom. Pharmacoepidemiol Drug Saf. 2021 Feb;30(2):237-47. doi: 10.1002/pds.5150
Gilsenan AW. Depression and pain in the primary care setting. Presented at the Correlation Between Depression and Pain: Creating a New Treatment Paradigm to Evaluate Cost and Caliber of Care. Symposia at the Academy of Managed Care Pharmacy 2002 Educational Conference; October 2002. Washington, DC.
Andrews EB, Mitchell AA, Seligman P, Cook SF, Gilsenan AW. Risk management: what are we driving, where are we going, and how will we know when we get there? Presented at the 18th International Conference on Pharmacoepidemiology; August 2002.
Longo C, Raskin J, Gilsenan AW, Corey-Lisle P, Hopkins JS, Sherrill BH. Prevalence of treatment-resistant depression in Saskatchewan - limitations of a claims-based analysis. Int J Neuropsychopharmacol. 2002 Jun 1;5(Suppl 1):S141. doi: 10.1017/S1461145702003176
Longo CJ, Raskin J, Gilsenan AW, Corey-Lisle P, Sherrill EH, Hopkins JS. Prevalence of treatment-resistant depression in Saskatchewan—limitations of a claims based analysis. Poster presented at the XXIII CINP Congress; 2002.
West SL, Dever JA, Troutman KS, Gilsenan AW, Glasser D. Methodology for conducting a national population-based prevalence study of erectile dysfunction. Poster presented at the 18th International Conference on Pharmacoepidemiology; 2002.
Gilsenan AW, Hopkins JS, Sherrill EH, Corey-Lisle PK, Longo CJ, Raskin J. Prevalence and costs of treatment-resistant depression in a Canadian claims database. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting; 2002.
Pendergast KB, Gilsenan AW, West SL, Swindle RW, Kroenke K. Differences in psychological and other quality of life dimensions in depressed patients identified as low-risk or high-risk for suicide. Poster presented at the 18th International Conference on Pharmacoepidemiology; 2002.
Von Scheele BG, Sherrill EH, Gilsenan AW, Devlin P. Therapeutic interchangeability of levothyroxine. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting; 2002.
Hopkins JS, Gilsenan AW, Sherrill EH, Cory-Lisle PK, Longo CJ, Raskin J. Methods to identify treatment-resistant depression in a Canadian claims database. Poster presented at the International Society for Pharmacoepidemiology Conference; 2002.